ArticleFrontiers in bioinformatics2025
Extracting a COVID-19 signature from a multi-omic dataset.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The complexity of COVID-19 requires approaches that extend beyond symptom-based descriptors. Multi-omic data, combining clinical, proteomic, and metabolomic information, offer a more detailed view of disease mechanisms and biomarker discovery. Methods: As part of a large-scale Quebec initiative, we collected extensive datasets from COVID-19 positive and negative patient samples. Using a multi-view machine learning framework with ensemble methods, we integrated thousands of features across clinical, proteomic, and metabolomic domains to classify COVID-19 status. We further applied a novel feature relevance methodology to identify condensed signatures. Results: Our models achieved a balanced accuracy of 89% ± 5% despite the high-dimensional nature of the data. Feature selection yielded 12- and 50-feature signatures that improved classification accuracy by at least 3% compared to the full feature set. These signatures were both accurate and interpretable. Discussion: This work demonstrates that multi-omic integration, combined with advanced machine learning, enables the extraction of robust COVID-19 signatures from complex datasets. The condensed biomarker sets provide a practical path toward improved diagnosis and precision medicine, representing a significant advancement in COVID-19 biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.